Taken together, these results indicated that high FBXW4 expression is associated with poor clinical outcome in AML patients, and particularly it is an independent poor survival factor in patients with intensive chemotherapy and allo-SCT therapy. Here, FBXW4 is linked to acute myeloid leukemia.